CBDA (the raw, unheated form of CBD) proved the most effective of five cannabinoids tested in an ALS mouse model, outperforming the standard ALS medication riluzole in preserving motor neurons and reducing neuroinflammation.
ALS researchers, neurologists, cannabinoid scientists, and patients interested in emerging ALS treatment research.
What the researchers found
Among five phytocannabinoids tested, CBDA at 10 mg/kg was the most effective, improving motor coordination, reducing neuronal cell death and neuroinflammation, and shifting microglia from pro-inflammatory to anti-inflammatory. CBDA showed superior neuroprotection compared to riluzole on most measures.
Why it matters
ALS has extremely limited treatment options. If CBDA consistently outperforms riluzole in preclinical models, it could warrant clinical trials as either an alternative or adjunct therapy.
The numbers in context
Optimal dose: 10 mg/kg CBDA. Five cannabinoids compared. Treatment period: day 65-90. Higher CBDA doses caused toxicity. CBD + riluzole combination did not enhance efficacy.
How the study worked
Preclinical study in Prp-hTDP-43(A315T) transgenic male mice, an ALS model, treated from early symptomatic (day 65) to advanced stages (day 90). Five cannabinoids compared, followed by CBDA dose-response testing and comparison with riluzole.
What this study cannot tell us
Only male mice were tested. The TDP-43 model represents one ALS subtype. Higher doses caused toxicity, suggesting a narrow therapeutic window.
How to read the evidence
Rigorous preclinical design with dose-response testing, active comparator, and mechanistic characterization, though limited to male mice and one ALS model.
When this study was published
2025 publication.
The bigger picture
CBDA is the acidic precursor to CBD found in raw cannabis. Its superior performance here suggests raw cannabinoid acids deserve more research attention, as they may have distinct therapeutic profiles.
Questions still open
- Why was the CBD-riluzole combination less effective than CBDA alone?
- Would CBDA show similar benefits in female mice or other ALS models?
Common questions
What is CBDA?
Why did combining CBD and riluzole not work better?
Read the original research
Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189, 118288
Citation
García-Toscano, Laura; Rodríguez-Cueto, Carmen; Furiano, Anna; Hind, William; de Lago, Eva; Fernández-Ruiz, Javier. (2025). Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189, 118288. https://doi.org/10.1016/j.biopha.2025.118288
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk